Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date | Expire Date | Purpose |
|---|---|---|---|---|---|
| NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed) | PAR-23-243 | NCI | This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for laboratory-based… More | ||
| Co-infection and Cancer (R01 Clinical Trial Not Allowed) | PAR-23-055 | NCI | This initiative seeks to enhance our mechanistic and epidemiologic understanding of infection-related cancers, with a focus on the etiologic roles of co-infection in cancer. Preference will be… More |
||
| Co-infection and Cancer (R21 Clinical Trial Not Allowed) | PAR-23-056 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently… More | ||
| Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required) | PAR-22-256 | NCI | Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate the development of evidence-based cancer-related interventions to improve health equity… More | ||
| NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional) | PAR-23-058 | NCI | This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports… More | ||
| Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed) | PAR-23-246 | NCI | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use… More | ||
| Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) | PAR-23-273 | NCI | This Notice of Funding Opportunity (NOFO) is intended to support mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer… More | ||
| Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional) | PAR-23-152 | NCI | Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional) | ||
| Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional) | PAR-23-153 | NCI | Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional) | ||
| National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional) | PAR-23-059 | NCI | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may… More |